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to TMA, the effect sizes were significantly larger in NMA. ConClusions: Network 
meta-analysis of multiple sclerosis trials shows fingolimod as the best treatment. 
Compared to traditional meta-analysis, network meta-analysis enables more robust 
estimation of effect sizes.
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objeCtives: Peripheral neuropathic pain (pNeP) refers to the pain associated with 
the condition of peripheral neuropathy. Postherpetic neuralgia (PHN) is one type of 
pNeP, which is the most common complication of herpes zoster. This study aims to 
determine the effectiveness of pregabalin compared with gabapentin in pNeP and 
PHN in China. Methods: We utilized a 12-week simulation model which tracked 
a cohort of 1,000 patients with pNeP or PHN only, by pain score. A pre-treatment 
distribution of pain scores was collected utilizing a local questionnaire of Chinese 
KOLs for pNeP and PHN. Treatment outcomes for pregabalin (150 – 600 mg) and 
gabapentin (2,400 mg) were taken from the published literature. Results: In the 
PHN scenario, pregabalin was associated with a lower average pain score compared 
with gabapentin (3.92 vs. 4.52). The difference in mean days of no or mild pain, mod-
erate pain, and severe pain were 8.82, -5.74, and -3.06, when comparing pregabalin 
and gabapentin, respectively. Pregabalin had more mean days with a > 30% (7.71 
days), 40% (8.97 days), and 50% reduction (9.97 days) in pain when compared with 
gabapentin. In the pNep scenario, pregabalin was associated with a lower average 
pain score compared with gabapentin (3.91 vs. 4.55). The difference in mean days 
of no or mild pain, moderate pain, and severe pain were 9.39, -5.56, and -3.82, when 
comparing pregabalin and gabapentin, respectively. Pregabalin had more mean days 
with a > 30% (8.77 days), 40% (9.81 days), and 50% reduction (10.55 days) in pain when 
compared with gabapentin. ConClusions: Pregabalin is an effective treatment for 
PHN and even for pNeP extensively. It leads to improved outcomes including lower 
pain scores and more days with no or mild pain.
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objeCtives: We studied the potential for new extended-half-life recombinant fac-
tor IX (rFIX) treatments to reduce the burden of injections and to prevent bleeding. 
We indirectly compared annualized bleed rates (ABRs) and factor consumption 
(FC) during prophylaxis and the FC and number of injections to treat a bleed with 
rFIX Fc fusion protein (rFIXFc) and conventional rFIX products based on estimates 
from published literature. Methods: A systematic review identified studies of 
routine prophylaxis in previously treated adults and adolescents with severe hae-
mophilia B for comparison with rFIXFc (Powell 2013; Arm 1, weekly prophylaxis). 
Comparisons were based on simple differences between studies in median weekly 
FC and mean ABRs during prophylaxis, and the median FC and numbers of injec-
tions per bleed. Median weekly FC during prophylaxis was reported or estimated 
from the reported dose and weekly number of injections; FC per bleed was esti-
mated from the reported dose and number of injections per bleed. The number 
of injections per bleed was calculated from the reported breakdown of bleeds 
by required number of injections or total number of injections divided by total 
bleeds. Results: Three conventional rFIX studies were included: Roth 2001 and 
Lambert 2007 (BeneFIX®) and Windyga 2014 (Rixubis®). During prophylaxis, the 
mean ABR was comparable or lower and FC was lower with rFIXFc compared with 
rFIX (weighted average ABR with rFIX= 4.0 vs. 3.1 with rFIXFc; weighted average 
increase in median weekly FC with rFIX= 108%). The number of injections and FC 
per bleed were also lower with rFIXFc (weighted average number of injections with 
conventional rFIX= 1.5 vs. 1.1 with rFIXFc; weighted average increase in median 
FC per bleed with rFIX= 49%). ConClusions: Indirect comparisons of published 
study results suggest that, compared with conventional rFIX, rFIXFc may require 
reduced FC for prophylaxis and bleed treatment while maintaining similar bleed-
ing rates for patients receiving prophylaxis.
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objeCtives: To model the impact of potential differences in adherence to rou-
tine prophylaxis with extended-half-life vs. conventional factor VIII and IX on 
bleeding efficacy for patients with severe haemophilia. Methods: Systematic 
literature reviews identified studies of routine prophylaxis in patients with severe 
haemophilia with conventional recombinant factor VIII (rFVIII) and IX (rFIX) for 
comparison with published studies of two extended-half-life agents (rFVIII and 
rFIX Fc fusion protein, rFVIIIFc and rFIXFc). We developed a model that extrapo-
lates the ABR for a given adherence level as the weighted average of two ABRs from 
clinical trials: those associated with prophylaxis (interpreted in the model as ABR 
associated with 100% adherence) and episodic treatment (interpreted as the ABR 
associated with 0% adherence). We used the model to extrapolate ABRs for con-
ventional products assuming real-world adherence of 76% of clinical trial levels, 
and ABRs for rFVIIIFc and rFIXFc at simulated adherence levels ≥ 76%. Extrapolated 
ABRs were compared using simple differences. We also mapped simulated adher-
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objeCtives: The objective of this literature review was to explore the existing 
evidences regarding the economic evaluation of multidisciplinary pain man-
agement services in managing people with fibromyalgia or chronic widespread 
pain Methods: Electronic search of Embase, MEDLINE, PsychoINFO, NHS EED, 
JBI, and Cochrane database was performed. Studies published from the time of 
the respective database inception to April 2015 were considered for inclusion in 
this review. The quality of studies was assessed using the Cochrane Back Review 
Group and the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS). Results: The literature review allowed retrieving 620 studies of which 
6 fulfilled the eligibility criteria. All included studies were economic evaluations 
alongside randomized clinical trials published between 1996 and 2015. Two were 
from the UK, two from Spain, and two from the Netherland. Risk of bias was high 
in two studies. The intervention, comparators, disciplines involved, and number of 
sessions were well described in most of the studies. variation between the included 
studies were in type of interventions, length of administration, follow-up period, 
and outcome measured. None of the studies met all CHEERS quality criteria. In 
Five studies, multidisciplinary pain management services were cost-effective at 
short-term follow up; however, this was not always maintained in long term follow-
up. ConClusions: Due to the high level of heterogeneity among selected studies, 
we were unable to make a definitive conclusion about the cost-effectiveness of 
pain management services in managing people with fibromyalgia or chronic wide-
spread pain. Multidisciplinary pain management services trials must be based on 
high methodological and economic quality to determine the cost-effectiveness of 
multidisciplinary pain management services.
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objeCtives: To better understand the impact of new extended-half-life recom-
binant factor VIII (rFVIII) treatments relative to conventional rFVIII, we indirectly 
compared published clinical study results of the factor consumption (FC) and num-
ber of injections to treat a bleed during episodic therapy and the FC and annualized 
bleeding rates (ABR) during prophylaxis with rFVIII Fc fusion protein (rFVIIIFc) and 
conventional rFVIII. Methods: A systematic review identified studies of routine 
prophylaxis in previously treated adults and adolescents with severe haemophilia 
A for comparison with rFVIIIFc (Mahlangu 2014, Arm 1, individualized prophylaxis). 
Comparisons were based on the simple differences between studies in median 
weekly FC, mean prophylaxis ABRs, and the median FC and numbers of injections 
per bleed. Median weekly FC was reported or estimated from the reported dose and 
weekly number of injections; FC per bleed was estimated from the reported dose 
and number of injections per bleed. The number of injections per bleed was calcu-
lated from the reported breakdown of bleeds by required number of injections or 
the total number of injections divided by total bleeds. Results: Four conventional 
rFVIII studies were included: Tarantino 2004 and Valentino 2012 (Advate®), Recht 
2009 (Xyntha®), and Pollmann 2007 (REFACTO®). ABR and weekly FC during proph-
ylaxis were lower with rFVIIIFc compared with each conventional rFVIII study 
(weighted average mean ABR with rFVIII= 5.2 vs. 2.9 with rFVIIIFc; weighted average 
increase in median weekly FC with rFVIII= 24%). The number of injections and FC 
per bleed were comparable or lower with rFVIIIFc vs. each rFVIII study (weighted 
average number of injections with rFVIII= 1.4 vs. 1.2 with rFVIIIFc; weighted aver-
age increase in median FC per bleed with rFVIII= 43%). ConClusions: Based on 
estimates from published literature, rFVIIIFc requires reduced FC for prophylaxis 
and bleed resolution compared with conventional rFVIII while maintaining similar 
or decreased bleeding rates for patients receiving prophylaxis.
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objeCtives: Several new agents have shown positive results in clinical trials for 
prevention of relapses in multiple sclerosis. The objective of this study was to com-
pare network meta-analysis results with traditional meta-analysis. Methods: A 
systematic literature search for randomized clinical trials for multiple sclerosis 
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar and 
Cochrane. Data was collected for the study type, methods, country and key find-
ings. Extracted study data included study design, patient charatcertristcis and MS 
related outcomes. A bayesian random effects network meta-analysis (NMA) model 
was developed in WinBUGS14. Results were compared to previously published tra-
ditional meta-analysis (TMA). Results: We identified 730 references and found 
10 randomized trials in 4095 patients with 2518 events. The drugs included in our 
study were interferon (IFN), glatiramer (GLAT, natalizumab (NAT) and fingolimod 
(FING). The Odds Ratios (ORs) for FING versus NAT was 1.66 (0.31 – 9.96),FING versus 
GLAT 2.19 (0.50 – 7.49), FING versus IFN 2.25 (0.90 – 5.57), FING versus PLB 4.42 (1.46 
– 14.87), NAT versus GLAT 1.32 (0.22 – 5.40), NAT versus IFN 1.321.35 (0.29 – 5.75), 
NAT versus PLB 2.68 (0.71 – 9.99), GLAT versus IFN 1.03 (0.42 – 3.16), GLAT versus 
PLB 2.04 (0.95 – 5.91), IFN-B versus PLB 1.97 (1.01 – 4.14). The probability to be best in 
preventing relapses was 75.9% for FING, 17.0% for NAT and 6.3% for GLAT. Compared 
